SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical firm targeted on growing and commercializing novel therapies for endocrine and neurological issues with vital unmet medical want, right now introduced that Javier Szwarcberg, M.D., M.P.H., Chief Government Officer, will current on the Guggenheim Securities Healthcare Innovation Convention on November 11, 2024, at 3:30 p.m. ET.
events can entry the stay webcast right here. An archived copy of the webcast will probably be out there on the occasions part of the corporate’s investor relations web site for about 90 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical firm targeted on growing and commercializing novel therapies for endocrine and neurological issues with vital unmet medical want. Spruce is growing its product candidate, tildacerfont, an oral, second-generation CRF1 receptor antagonist, for the remedy of congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS) and main depressive dysfunction (MDD). To study extra, go to www.sprucebio.com and comply with us on X, LinkedIn, Fb (NASDAQ:) and YouTube.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20241028643351/en/
Media
Katie Seashore Oltsik
Inizio Evoke Comms
(937) 232-4889
Katherine.Seashore@inizioevoke.com
media@sprucebio.com
Buyers
Samir Gharib
President and CFO
Spruce Biosciences, Inc.
buyers@sprucebio.com
Supply: Spruce Biosciences, Inc.